NeoPharm (Daejeon) Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 184

Employees

  • Stock Symbol
  • 092730

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $16.19
  • (As of Friday Closing)

NeoPharm (Daejeon) General Information

Description

NeoPharm Co Ltd is a South Korean company operating in the household and personal products. The products of the company include skin care brand, skin barrier special dermo cosmetic brand, hospital functional products, and life moisturizing body professional brand.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 309-8 Techno 2-ro
  • Daejeon, Yuseong
  • South Korea
+82
Primary Industry
Personal Products
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Corporate Office
  • 309-8 Techno 2-ro
  • Daejeon, Yuseong
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeoPharm (Daejeon) Stock Performance

As of 13-Nov-2026, NeoPharm (Daejeon)’s stock price is $16.19. Its current market cap is $253M with 15.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.19 $16.68 $10.15 - $18.70 $253M 15.6M 62.1K $1.25

NeoPharm (Daejeon) Financials Summary

As of 31-Dec-2025, NeoPharm (Daejeon) has a trailing 12-month revenue of $92.9M.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 107,544 107,544 47,926 60,278
Revenue 92,882 92,882 87,226 74,270
EBITDA 22,258 22,258 21,433 20,253
Net Income 19,550 19,550 16,904 17,754
Total Assets 151,257 151,257 130,648 137,706
Total Debt 1,330 1,330 427 827
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NeoPharm (Daejeon) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NeoPharm (Daejeon)‘s full profile, request access.

Request a free trial

NeoPharm (Daejeon) Patents

NeoPharm (Daejeon) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026084206-A1 Cosmetic composition for inhibiting sebum secretion Pending 14-Oct-2024
WO-2026084205-A1 Cosmetic material composition for skin anti-inflammation and skin soothing Pending 14-Oct-2024
US-20220142888-A1 Composition for improving skin conditions Inactive 11-Nov-2020
US-20240082131-A1 Composition for improving skin conditions Inactive 11-Nov-2020
US-11607378-B2 Cosmetic composition comprising amide-based compound Active 13-Mar-2020 A61K8/42
To view NeoPharm (Daejeon)’s complete patent history, request access »

NeoPharm (Daejeon) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeoPharm (Daejeon) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NeoPharm (Daejeon)‘s full profile, request access.

Request a free trial

NeoPharm (Daejeon) Investments (1)

NeoPharm (Daejeon)’s most recent deal was a Corporate with GPSkin for . The deal was made on 01-Jan-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
GPSkin 01-Jan-2016 Corporate Monitoring Equipment
To view NeoPharm (Daejeon)’s complete investments history, request access »

NeoPharm (Daejeon) ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Household Products

Industry

Rank

Percentile

Personal Products

Subindustry

Rank

Percentile

To view NeoPharm (Daejeon)’s complete esg history, request access »

NeoPharm (Daejeon) Exits (1)

NeoPharm (Daejeon)’s most recent exit was on 01-Jan-2016 from GPSkin. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
GPSkin 01-Jan-2016 Completed
To view NeoPharm (Daejeon)’s complete exits history, request access »

NeoPharm (Daejeon) FAQs

  • When was NeoPharm (Daejeon) founded?

    NeoPharm (Daejeon) was founded in 2000.

  • Where is NeoPharm (Daejeon) headquartered?

    NeoPharm (Daejeon) is headquartered in Daejeon, South Korea.

  • What is the size of NeoPharm (Daejeon)?

    NeoPharm (Daejeon) has 184 total employees.

  • What industry is NeoPharm (Daejeon) in?

    NeoPharm (Daejeon)’s primary industry is Personal Products.

  • Is NeoPharm (Daejeon) a private or public company?

    NeoPharm (Daejeon) is a Public company.

  • What is NeoPharm (Daejeon)’s stock symbol?

    The ticker symbol for NeoPharm (Daejeon) is 092730.

  • What is the current stock price of NeoPharm (Daejeon)?

    As of 13-Nov-2026 the stock price of NeoPharm (Daejeon) is $16.19.

  • What is the current market cap of NeoPharm (Daejeon)?

    The current market capitalization of NeoPharm (Daejeon) is $253M.

  • What is NeoPharm (Daejeon)’s current revenue?

    The trailing twelve month revenue for NeoPharm (Daejeon) is $92.9M.

  • What is NeoPharm (Daejeon)’s annual earnings per share (EPS)?

    NeoPharm (Daejeon)’s EPS for 12 months was $1.25.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process